Zhejiang Shengda Bio-Pharm Hits Day High with 10.04% Surge

Zhejiang Shengda Bio-Pharm Co., Ltd. has experienced a significant surge in its stock price, gaining 10.04% on August 21, 2026. The stock reached an intraday high of CNY 14.03, marking a notable performance against the backdrop of the China Shanghai Composite, which only saw a marginal increase of 0.04% on the same day. In terms of performance metrics, Zhejiang Shengda has shown resilience over the past month, with a remarkable 35.16% increase, contrasting sharply with the Shanghai Composite's 1.06% gain. However, the company has faced challenges over the longer term, with a year-to-date decline of 20.82% and a one-year performance drop of 24.73%. Despite these fluctuations, the company has reported positive results in its last three consecutive quarters, showcasing an operating cash flow peak of CNY 133.3 million and a net profit growth of 77.05% in the first half of the year. With a market capitalization of CNY 966 million, Zhejiang Shengda operates within the pharmaceuticals and biotechnology sector, characterized by a P/E ratio of 36.00 and a dividend yield of 1.77%.